Estimated reading time: 6 minutes · Last updated:
Palantir NHS data has become the subject of a coordinated legal backlash: objection filings to NHS England show that over 44,000 people have submitted formal objections under the UK GDPR asking NHS England to bar the Federated Data Platform (FDP) powered by Palantir from handling their personal health information. The objections invoke article 21 of the UK GDPR and ask the NHS to halt processing of objectors’ records unless it can show a compelling reason to continue. The dispute sits alongside public protests, petition drives against a £330m contract with Palantir and political pressure on a seven‑year deal due to take effect in February 2027.
Key takeaways
- Number of objections: Objection filings show that over 44,000 people have asked for their data not to be shared with or used by the Federated Data Platform.
- Legal basis: The formal complaints invoke article 21 of the UK General Data Protection Regulation.
- Contract value and timing: Campaigners oppose a £330m, seven‑year deal with Palantir that is due to take effect in February 2027.
- Palantir’s claimed benefits: Palantir says trusts using its software recorded 117,000 additional operations and reported a 14.3% reduction in long‑stay discharge delays and a 5.6% improvement in cancer decisions within 28 days.
Table of contents
- Key takeaways
- Why more than 44,000 people used article 21 of the UK GDPR
- Palantir’s claims and the figures NHS trusts cite
- Politics, protests and reputational pressure
- Immediate consequences for NHS practice and what organisations must do
- How the dispute could unfold
- What to be careful about
- Frequently asked questions
Why more than 44,000 people used article 21 of the UK GDPR
The objections are formal rights under article 21 of the UK General Data Protection Regulation, which lets individuals object to processing where they believe it affects their rights or freedoms. Objectors cited loss of trust in NHS confidentiality when Palantir is involved and asked NHS England to stop processing their personal data through the FDP while each objection is assessed.
The legal consequence is specific: NHS bodies must cease processing the objector’s data unless they can identify a “compelling reason” to continue. That places an operational burden on NHS organisations that are using the FDP: they must either establish a lawful, overriding basis for continued processing or suspend use of the affected records for those objectors.
Those who organised the campaign framed the rights exercise as a mass exercise of statutory safeguards. Veronica Hawking of 38 Degrees coordinated the objections and said the scale should act as a wake‑up call for the government; 38 Degrees said it organised the action.
Palantir’s claims and the figures NHS trusts cite
Palantir and NHS England present the FDP as a tool to connect clinical and operational data across trusts. Palantir’s executive vice‑president for UK and Europe, Louis Mosley, said the company’s software has helped trusts record 117,000 additional operations and achieve a 14.3% reduction in discharge delays for long‑stay patients, along with a 5.6% improvement in the number of people receiving cancer decisions within 28 days.
Palantir also told the NHS that patient data on the FDP would be handled only according to NHS instructions and that the data would remain in the UK. Those technical and contractual limits are central to the company’s defence against objections and to NHS England’s assurance that suppliers cannot use the data for their own purposes.
Palantir published numerical claims and publicly characterised critics; Mosley used the phrase "Palantir derangement syndrome" when dismissing some opponents. Those claims and counters frame the operational question NHS managers must now answer when responding to individual objections.
Politics, protests and reputational pressure
Campaigners cite Palantir’s past work with the Israeli military and with US immigration enforcement (ICE) as part of their argument. Amnesty International and patient group Just Treatment staged a protest outside Palantir’s London offices using a van styled as a shot‑up Palestinian ambulance; the two groups said they carried out the stunt.
Two House of Commons select committees have urged Labour to use a break clause in the contract, and petition drives have attracted hundreds of thousands of signatures demanding cancellation of the £330m deal. The row has become a decision point for regional and national politicians: contract terms indicate Andy Burnham will be required to make a choice to back or axe the Palantir deal within months.
Political pressure and organised public objection create both reputational risk for Palantir and a governance problem for NHS England: officials must weigh operational claims about reduced waiting times and improved throughput against the scale of public distrust and the legal requirement to respond to individual data objections.
Immediate consequences for NHS practice and what organisations must do
NHS England has said that organisations remain in control of their data within the FDP and that suppliers cannot access it for their own purposes; it also stated it will respond to the objection requests in line with data protection law. Practically, that means each trust using the FDP must review objections, decide whether to suspend processing of an objector’s records, and document any compelling reasons to continue.
For patients who object, the stated effect can be a suspension of processing of their records through the FDP until the NHS issues a formal response. The campaigners have also requested that processing be halted while the main objection is considered, which increases the administrative workload for trust data teams and for NHS England.
Where a trust cannot justify continued processing on grounds that override the objection, the trust will be required to stop using that person’s data on the FDP. NHS England has acknowledged concerns about the scale of claimed benefits, which tightens the standard of proof trusts will need if they intend to maintain FDP use for objectors.
| Party | Role/Claim | Figure or date cited |
|---|---|---|
| Palantir | Operator of the Federated Data Platform; says software improves care | 117,000 additional operations; 14.3% reduction in long‑stay discharge delays; 5.6% improvement in 28‑day cancer decisions |
| 38 Degrees | Co‑ordinator of the legal objections campaign | More than 44,000 objections filed |
| UK government / Parliament | Political oversight and contract scrutiny | £330m contract; seven‑year deal due to take effect February 2027 |
How the dispute could unfold
The case for
- If NHS England and trusts can show measurable, trust‑guided public‑health benefits from the FDP, they may lawfully continue processing for objectors by documenting a compelling reason under article 21.
- A clear, documented separation of supplier access and UK data residency — as Palantir asserts — could reduce the number of sustained objections and limit reputational damage.
The case against
- If trusts cannot demonstrate the scale of benefits Palantir claims, the legal obligation to stop processing objectors’ records could force local suspension of FDP use and complicate operational planning.
- Sustained public and political pressure, including petitions and select‑committee scrutiny, could prompt ministers to exercise the contract break clause before the seven‑year deal begins in February 2027.
What to be careful about
- Operational disruption: trusts may need to suspend processing for thousands of individual records while objections are assessed.
- Reputational and political risk: protests and parliamentary committee calls risk earlier termination or renegotiation of the £330m contract.
- Legal exposure: if NHS organisations fail to apply article 21 processes correctly they could face regulatory challenge from the ICO.
The bottom line
The mass rights exercise converts individual concerns about confidentiality and supplier history into a legal and operational test for NHS England and for trusts using the Federated Data Platform. More than 44,000 objections force data controllers to choose, case by case, whether a documented, compelling public‑health reason outweighs a person’s objection under article 21. That legal requirement, together with protests, petitions and parliamentary scrutiny over a £330m contract due to take effect in February 2027, makes the coming months a decisive period for how the NHS balances data use, governance and public trust.
What to watch
- watch for the contract taking effect in February 2027 and any ministerial decision to exercise the deal’s break clause; February 2027 is the date given in the contract details
- watch for Andy Burnham’s decision on whether to back or axe the Palantir deal; no date has been set for that decision
Frequently asked questions
How many people have objected to Palantir handling NHS data?
Over 44,000 individuals have lodged formal objections under article 21 of the UK GDPR, asking NHS England to stop processing their records through the Federated Data Platform.
Under what legal right were the objections made?
The objections cite article 21 of the UK General Data Protection Regulation; that right lets individuals object to processing and requires data controllers to stop unless they can demonstrate a compelling reason to continue.
What are the practical effects for patients who object?
Objectors have asked that processing of their records via the FDP be halted while requests are assessed; if a trust cannot show a compelling reason it will need to suspend processing for that person.
What figures has Palantir given to justify the FDP?
Palantir says trusts using its software recorded 117,000 additional operations, a 14.3% reduction in long‑stay discharge delays and a 5.6% improvement in 28‑day cancer decision figures.
Related reading
